Metabolomic analysis of serum from obese adults with hyperlipemia by UHPLC‐Q‐TOF MS/MS. (5th June 2015)

• Record Type: Journal Article
• Authors: Wang, Yang; Liu, Desheng; Li, Yue; Guo, Lei; Cui, Yinghua; Zhang, Xin; Li, Enyou
• Is Part Of: Biomedical chromatography. Volume 30:Number 1(2016:Jan.)
• Page Start: 48
• Page End: 54
• Publication Date: 2015-06-05
• Subjects: metabonomics -- UHPLC‐Q‐TOF MS/MS -- obesity -- metabolism; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.3491
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: The prevalence of obesity has dramatically increased and poses a major threat to human health. Obesity often accompanies hyperlipemia, which is strongly related to the occurrence and development of obesity‐related chronic diseases. Differences in metabolomic profiling of serum between obese (with hyperlipemia) and normal‐weight men ( n = 30 in each group) were investigated using ultrahigh‐pressure liquid chromatography–quadrupole–time of flight mass spectrometry (UHPLC‐Q‐TOF MS/MS) and partial least‐squares–discriminant analysis (PLS‐DA). Obese men showed higher levels of weight, body mass index, fat mass, systolic blood pressure, fasting plasma glucose, triglyeride, total cholesterol, insulin, HOMA‐IR and high‐sensitivity CRP. Obese and normal‐weight groups were clearly discriminated from each other on a PLS‐DA score plot and nine major metabolites contributing to the discrimination were assigned, including increased 2‐octenoylcarnitine, eicosadienoic acid, 12‐hydroperoxyeicosatetraenoic acid, 4‐hydroxyestrone sulfate, lysoPE[18:1(11 Z )/0:0], thromboxane B2 and pyridinoline and decreased vitamin D3 glucosiduronate and 9, 10‐DHOME. These metabolites were associated with lipid metabolism and obesity‐related diseases, and reflected the metabolic differences between normal and obese men, which may be important for future clinical diagnosis, treatment and assessment of the therapeutic effect on obesity‐related chronic disease. Copyright © 2015 John Wiley & Sons, Ltd.